Tamar S. Polonsky to Hydroxymethylglutaryl-CoA Reductase Inhibitors
This is a "connection" page, showing publications Tamar S. Polonsky has written about Hydroxymethylglutaryl-CoA Reductase Inhibitors.
Connection Strength
1.222
-
Lower Extremity Peripheral Artery Disease Without Chronic Limb-Threatening Ischemia: A Review. JAMA. 2021 Jun 01; 325(21):2188-2198.
Score: 0.595
-
Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy. Am J Cardiol. 2008 Apr 17; 101(8A):27B-35B.
Score: 0.240
-
Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): Trial design and rationale. J Am Geriatr Soc. 2023 06; 71(6):1701-1713.
Score: 0.170
-
Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines. Circulation. 2015 Sep 08; 132(10):916-22.
Score: 0.099
-
Coronary artery calcium score. JAMA. 2014 Aug 27; 312(8):837-8.
Score: 0.093
-
Utility of Nontraditional Risk Markers in Atherosclerotic Cardiovascular Disease Risk Assessment. J Am Coll Cardiol. 2016 Jan 19; 67(2):139-147.
Score: 0.026